Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 20/20 | 1.00 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18982595 | 1.00 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982050 | 1.00 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982589 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982803 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982320 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982355 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982903 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982066 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982206 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 | |
| SCHEMBL18982203 | 0.92 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108738320-B | cGMP modulators for the treatment of cardiovascular diseases | 默沙东公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2018-10-25 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885 |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885 |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | GUCY1A1 1/4885GUCY1B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.